Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:03 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Vedolizumab Monotherapy Vs Combination Therapy With Tacrolimus in UC
NCT02954159 · Medical College of Wisconsin · PHASE3 · terminated · last registry update 2020-09-03 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “insufficient enrollment” | – | Registry record, Medical College of Wisconsin |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against FKBP1A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-08-03Phase 3 first posted: Katarzyna Kotulska, Vigabatrin + Rapamycin (NCT04987463)
- 2021-07-28Results posted on the registry: University of Cincinnati, Alemtuzumab + rabbit antithymocyte globulin (NCT01729494)
- 2021-05-07Phase 3 first posted: Bristol-Myers Squibb, Belatacept + Tacrolimus (NCT04877288)
- 2021-04-06Results posted on the registry: CellTrans Inc., Islets of Langerhans transplantation (NCT00679042)
- 2020-11-16Phase 3 first posted: Hoffmann-La Roche, Obinutuzumab + Tacrolimus (NCT04629248)
- 2020-09-24Phase 3 first posted: Vastra Gotaland Region, Tocilizumab (NCT04561986)
- 2019-12-12Phase 3 first posted: Merck Sharp & Dohme LLC, Belzutifan + Everolimus (NCT04195750)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision